TriPath Imaging says Melastatin gene expression as measured by its product associated with a new chromogenic, in-situ hybridzation (CISH) method is an indicator for overall survival in melanoma.

The Burlington-based company presented the independent study at the 93rd Annual Meeting of the United States and Canadian Academy of Pathology (USCAP) in Vancouver, British Columbia.

This research study’s objective was to evaluate the new CISH method developed by TriPath Oncology, a wholly owned subsidiary of TriPath Imaging, for determining Melastatin expression in primary and metastatic melanoma and to correlate these findings with clinical outcome.

Melastatin is a melanocyte-specific gene, discovered by Millennium Pharmaceuticals, that has been identified as a potential prognostic biomarker of clinical outcome in patients suffering from cutaneous melanoma, a cancerous lesion of skin.

“This study demonstrates that measurement of Melastatin expression using our assay provides independent prognostic information that may be useful in the clinical assessment of melanoma–,” said Paul Sohmer, chairman, president and CEO of TriPath. “The presentation of these data is an important milestone that marks the continued progress made in TriPath Imaging’s molecular diagnostic product development program. These successful efforts have been led by a talented team at our research and development subsidiary, TriPath Oncology.”

As a result, Sohmer has promoted Johnny Powers to senior vice president of the company. Powers previously served as general manager of TriPath Oncology since 2002.

“The progress made by our team at TriPath Oncology is clearly a reflection of the outstanding leadership provided by Johnny–,” said Sohmer. “This promotion recognizes his leadership contribution to date as well as the significance we attach to TriPath Oncology and its development programs going forward.”

TriPath Imaging: